Switch theme
Sign up to access all valuation multiples
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
2015
55
LTM Revenue $1.3M
LTM EBITDA -$57.1M
-$1.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Camp4 Therapeutics has a last 12-month revenue (LTM) of $1.3M and a last 12-month EBITDA of -$57.1M.
In the most recent fiscal year, Camp4 Therapeutics achieved revenue of $0.7M and an EBITDA of -$51.4M.
Camp4 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Camp4 Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | XXX | $0.7M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$57.1M | XXX | -$51.4M | XXX | XXX | XXX |
| EBITDA Margin | -4368% | XXX | -7882% | XXX | XXX | XXX |
| EBIT | -$55.5M | XXX | -$53.1M | XXX | XXX | XXX |
| EBIT Margin | -4241% | XXX | -8142% | XXX | XXX | XXX |
| Net Profit | -$53.7M | XXX | -$51.8M | XXX | XXX | XXX |
| Net Margin | -4103% | XXX | -7943% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Camp4 Therapeutics's stock price is $2.
Camp4 Therapeutics has current market cap of $39.6M, and EV of -$1.8M.
See Camp4 Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.8M | $39.6M | XXX | XXX | XXX | XXX | $-7.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Camp4 Therapeutics has market cap of $39.6M and EV of -$1.8M.
Camp4 Therapeutics's trades at -2.8x EV/Revenue multiple, and 0.0x EV/EBITDA.
Equity research analysts estimate Camp4 Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Camp4 Therapeutics has a P/E ratio of -0.7x.
See valuation multiples for Camp4 Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39.6M | XXX | $39.6M | XXX | XXX | XXX |
| EV (current) | -$1.8M | XXX | -$1.8M | XXX | XXX | XXX |
| EV/Revenue | -1.4x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/Gross Profit | -1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCamp4 Therapeutics's last 12 month revenue growth is 16%
Camp4 Therapeutics's revenue per employee in the last FY averaged $12K, while opex per employee averaged $1.0M for the same period.
Camp4 Therapeutics's rule of 40 is -14327% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Camp4 Therapeutics's rule of X is -4328% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Camp4 Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -4368% | XXX | -7882% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | -14327% | XXX | -7866% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4328% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $12K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5954% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8242% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Camp4 Therapeutics acquired XXX companies to date.
Last acquisition by Camp4 Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Camp4 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Camp4 Therapeutics founded? | Camp4 Therapeutics was founded in 2015. |
| Where is Camp4 Therapeutics headquartered? | Camp4 Therapeutics is headquartered in United States of America. |
| How many employees does Camp4 Therapeutics have? | As of today, Camp4 Therapeutics has 55 employees. |
| Who is the CEO of Camp4 Therapeutics? | Camp4 Therapeutics's CEO is Mr. Joshua Mandel-Brehm. |
| Is Camp4 Therapeutics publicy listed? | Yes, Camp4 Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Camp4 Therapeutics? | Camp4 Therapeutics trades under CAMP ticker. |
| When did Camp4 Therapeutics go public? | Camp4 Therapeutics went public in 2024. |
| Who are competitors of Camp4 Therapeutics? | Similar companies to Camp4 Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Camp4 Therapeutics? | Camp4 Therapeutics's current market cap is $39.6M |
| What is the current revenue of Camp4 Therapeutics? | Camp4 Therapeutics's last 12 months revenue is $1.3M. |
| What is the current revenue growth of Camp4 Therapeutics? | Camp4 Therapeutics revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Camp4 Therapeutics? | Current revenue multiple of Camp4 Therapeutics is -1.4x. |
| Is Camp4 Therapeutics profitable? | Yes, Camp4 Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Camp4 Therapeutics? | Camp4 Therapeutics's last 12 months EBITDA is -$57.1M. |
| What is Camp4 Therapeutics's EBITDA margin? | Camp4 Therapeutics's last 12 months EBITDA margin is -4368%. |
| What is the current EV/EBITDA multiple of Camp4 Therapeutics? | Current EBITDA multiple of Camp4 Therapeutics is 0.0x. |
| What is the current FCF of Camp4 Therapeutics? | Camp4 Therapeutics's last 12 months FCF is -$50.2M. |
| What is Camp4 Therapeutics's FCF margin? | Camp4 Therapeutics's last 12 months FCF margin is -3836%. |
| What is the current EV/FCF multiple of Camp4 Therapeutics? | Current FCF multiple of Camp4 Therapeutics is 0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
